HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury

Files in This Item:
J Gastroenterol_49(2)_239-244.pdf257.66 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/58005

Title: A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury
Authors: Kurokawa, Sei Browse this author
Katsuki, Shinichi Browse this author
Fujita, Tomoki Browse this author
Saitoh, Yusuke Browse this author
Ohta, Hidetoshi Browse this author
Nishikawa, Kouji Browse this author
Sato, Yasushi Browse this author
Sato, Yasuhiro Browse this author
Ohira, Koji Browse this author
Yamada, Masataka Browse this author
Kato, Mototsugu Browse this author →KAKEN DB
Keywords: NSAID
Aspirin
Small intestinal injury
Capsule endoscopy
Nutritional parameter
Issue Date: Feb-2014
Publisher: Springer japan kk
Journal Title: Journal of gastroenterology
Volume: 49
Issue: 2
Start Page: 239
End Page: 244
Publisher DOI: 10.1007/s00535-013-0805-2
PMID: 23595613
Abstract: It is not clear what kind of drug is appropriate to heal NSAID-induced enteropathy. Several reports showed the preventive effect of prostaglandin analogue or inducer using healthy subjects who took NSAIDs. However there was no report for healing effect and for patients. The aim of this study was to evaluate the healing effect of rebamipide in patients with NSAIDs-induced enteropathy. In addition, we evaluated for nutritional parameter. This study was conducted as a randomized, double-blinded, placebo-controlled, multicenter trial. Study protocol was approved by each hospital's ethical committees. Patients with LDA and/or NSAID more than 3 months were enrolled. Patients with enteropathy were divided into the placebo and the rebamipide groups. Rebamipide 100 mg three times daily was administered during 4 weeks. Capsule endoscopies were performed at 0 and 4 week. The number of small intestinal ulcer and erosion were evaluated. Total protein was analyzed as nutritional parameter. Sixty one participants were completed this study. Change in number of small intestinal erosion in the rebamipide group was -2.5 +/- A 3.4, and 2.1 +/- A 3.9 in the placebo group (P < 0.0001). Change in number of small intestinal ulcer in the rebamipide group was -0.5 +/- A 1.6, and 0.1 +/- A 0.7 in the placebo group (P = 0.024). Change in serum total protein levels in the rebamipide group was 0.06 +/- A 0.36, and -0.27 +/- A 0.34 in the placebo group (P = 0.0005). Rebamipide has not only the healing effect for NSAIDs-induced enteropathy compared with placebo, but the improvement of nutritional condition. These results showed a tentative therapeutical strategy for chronic NSAIDs users.
Rights: The final publication is available at link.springer.com
Type: article (author version)
URI: http://hdl.handle.net/2115/58005
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 加藤 元嗣

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

Feedback - Hokkaido University